Matthew Fomonyuy Yuyun, Ph.D., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adrenomedullin | 2 | 2017 | 87 | 1.150 |
Why?
|
| Albuminuria | 6 | 2005 | 674 | 1.120 |
Why?
|
| Arrhythmias, Cardiac | 5 | 2022 | 2144 | 0.940 |
Why?
|
| Bradycardia | 3 | 2020 | 285 | 0.900 |
Why?
|
| Atrioventricular Block | 2 | 2018 | 110 | 0.750 |
Why?
|
| Defibrillators, Implantable | 4 | 2021 | 1405 | 0.730 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2021 | 494 | 0.690 |
Why?
|
| Sick Sinus Syndrome | 1 | 2018 | 44 | 0.670 |
Why?
|
| Biopterin | 1 | 2018 | 67 | 0.660 |
Why?
|
| Tetrahydrofolates | 1 | 2018 | 60 | 0.660 |
Why?
|
| Electric Countershock | 1 | 2021 | 515 | 0.650 |
Why?
|
| Device Removal | 1 | 2021 | 648 | 0.560 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2021 | 1502 | 0.550 |
Why?
|
| Cardiovascular Diseases | 8 | 2021 | 14438 | 0.450 |
Why?
|
| Heart Failure | 5 | 2022 | 10041 | 0.440 |
Why?
|
| Nitric Oxide | 1 | 2018 | 2123 | 0.350 |
Why?
|
| Africa South of the Sahara | 3 | 2020 | 708 | 0.350 |
Why?
|
| Myocardial Infarction | 4 | 2017 | 11401 | 0.320 |
Why?
|
| Hemodynamics | 1 | 2018 | 4214 | 0.320 |
Why?
|
| Retinal Diseases | 2 | 2022 | 669 | 0.290 |
Why?
|
| Hypoglycemia | 2 | 2022 | 813 | 0.280 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2020 | 844 | 0.270 |
Why?
|
| Endothelium, Vascular | 1 | 2018 | 4586 | 0.270 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2022 | 11090 | 0.260 |
Why?
|
| Morbidity | 2 | 2020 | 1715 | 0.260 |
Why?
|
| Genital Diseases, Male | 1 | 2004 | 85 | 0.250 |
Why?
|
| Primary Dysautonomias | 1 | 2022 | 30 | 0.230 |
Why?
|
| Atrial Fibrillation | 2 | 2022 | 4562 | 0.200 |
Why?
|
| Catheter Ablation | 1 | 2013 | 2558 | 0.190 |
Why?
|
| Incidence | 7 | 2022 | 20731 | 0.180 |
Why?
|
| Diabetic Neuropathies | 1 | 2003 | 419 | 0.180 |
Why?
|
| Risk Factors | 15 | 2022 | 70866 | 0.180 |
Why?
|
| Cardiology | 2 | 2020 | 1645 | 0.180 |
Why?
|
| Ventricular Function, Left | 2 | 2021 | 3364 | 0.170 |
Why?
|
| Stroke Volume | 2 | 2021 | 4486 | 0.170 |
Why?
|
| Urinary Tract Infections | 1 | 2004 | 780 | 0.170 |
Why?
|
| Long QT Syndrome | 1 | 2022 | 421 | 0.160 |
Why?
|
| Developed Countries | 1 | 2020 | 409 | 0.160 |
Why?
|
| Education | 1 | 2020 | 543 | 0.150 |
Why?
|
| Minority Groups | 2 | 2020 | 1088 | 0.150 |
Why?
|
| Atrial Flutter | 1 | 2018 | 252 | 0.140 |
Why?
|
| Heart Rate | 3 | 2022 | 4097 | 0.140 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2018 | 712 | 0.130 |
Why?
|
| Diabetic Nephropathies | 1 | 2022 | 1037 | 0.130 |
Why?
|
| Homocysteine | 1 | 2018 | 659 | 0.130 |
Why?
|
| Humans | 33 | 2022 | 715777 | 0.130 |
Why?
|
| Middle Aged | 20 | 2022 | 214639 | 0.120 |
Why?
|
| Action Potentials | 1 | 2021 | 1780 | 0.120 |
Why?
|
| Survival Rate | 3 | 2020 | 13206 | 0.120 |
Why?
|
| Electric Power Supplies | 1 | 2013 | 79 | 0.120 |
Why?
|
| Cause of Death | 1 | 2004 | 3612 | 0.120 |
Why?
|
| Pacemaker, Artificial | 1 | 2018 | 767 | 0.110 |
Why?
|
| Electrocardiography | 4 | 2022 | 6386 | 0.110 |
Why?
|
| Lyme Disease | 1 | 2018 | 605 | 0.110 |
Why?
|
| Primary Prevention | 1 | 2020 | 1161 | 0.110 |
Why?
|
| Folic Acid | 1 | 2018 | 1252 | 0.100 |
Why?
|
| Predictive Value of Tests | 4 | 2015 | 15199 | 0.100 |
Why?
|
| Income | 1 | 2020 | 1822 | 0.100 |
Why?
|
| Aged | 13 | 2021 | 162448 | 0.100 |
Why?
|
| England | 3 | 2014 | 517 | 0.100 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2021 | 1358 | 0.100 |
Why?
|
| Prognosis | 5 | 2017 | 29005 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2017 | 12456 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 6722 | 0.090 |
Why?
|
| Male | 20 | 2022 | 350324 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 12480 | 0.090 |
Why?
|
| Female | 20 | 2022 | 377204 | 0.090 |
Why?
|
| Coronary Disease | 1 | 2004 | 6150 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2021 | 62004 | 0.080 |
Why?
|
| Age Distribution | 2 | 2004 | 2942 | 0.080 |
Why?
|
| Autonomic Nervous System | 2 | 2022 | 676 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2018 | 3129 | 0.070 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2014 | 920 | 0.070 |
Why?
|
| Time Factors | 3 | 2018 | 40875 | 0.070 |
Why?
|
| Hydrocortisone | 1 | 2014 | 1735 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2018 | 1738 | 0.070 |
Why?
|
| Adult | 15 | 2022 | 212266 | 0.070 |
Why?
|
| Dietary Supplements | 1 | 2018 | 3110 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2021 | 8544 | 0.070 |
Why?
|
| Risk Assessment | 4 | 2021 | 23464 | 0.070 |
Why?
|
| Stroke | 2 | 2004 | 9505 | 0.070 |
Why?
|
| Cameroon | 1 | 2004 | 63 | 0.060 |
Why?
|
| Heart Arrest | 1 | 2014 | 1374 | 0.060 |
Why?
|
| Urethral Stricture | 1 | 2004 | 58 | 0.060 |
Why?
|
| Registries | 1 | 2020 | 8045 | 0.060 |
Why?
|
| Prevalence | 3 | 2004 | 14911 | 0.060 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 6289 | 0.050 |
Why?
|
| Prospective Studies | 5 | 2022 | 51315 | 0.050 |
Why?
|
| Morocco | 1 | 2020 | 27 | 0.050 |
Why?
|
| Africa, Northern | 1 | 2020 | 75 | 0.050 |
Why?
|
| Prostatic Hyperplasia | 1 | 2004 | 506 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2013 | 5922 | 0.050 |
Why?
|
| Heart | 2 | 2022 | 4315 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 662 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2004 | 2371 | 0.040 |
Why?
|
| Cardiology Service, Hospital | 1 | 2020 | 255 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2004 | 800 | 0.040 |
Why?
|
| Cohort Studies | 4 | 2022 | 40029 | 0.040 |
Why?
|
| Capacity Building | 1 | 2020 | 260 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2005 | 1397 | 0.040 |
Why?
|
| Ceftriaxone | 1 | 2018 | 150 | 0.040 |
Why?
|
| Doxycycline | 1 | 2018 | 310 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 17409 | 0.040 |
Why?
|
| HIV Infections | 1 | 2021 | 15784 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2004 | 1356 | 0.030 |
Why?
|
| South Africa | 1 | 2020 | 1594 | 0.030 |
Why?
|
| Hypertension | 2 | 2005 | 8270 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 58323 | 0.030 |
Why?
|
| Wales | 1 | 2014 | 85 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2018 | 23729 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 39300 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2020 | 72443 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2006 | 5265 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2004 | 7015 | 0.030 |
Why?
|
| Mass Screening | 2 | 2006 | 5209 | 0.030 |
Why?
|
| Medical Audit | 1 | 2014 | 480 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2020 | 3956 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 1437 | 0.030 |
Why?
|
| Developing Countries | 1 | 2004 | 2737 | 0.030 |
Why?
|
| Ventricular Fibrillation | 1 | 2014 | 534 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2004 | 9984 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2013 | 15079 | 0.020 |
Why?
|
| Exercise Test | 1 | 2018 | 2110 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2022 | 2775 | 0.020 |
Why?
|
| Sex Factors | 1 | 2004 | 10666 | 0.020 |
Why?
|
| Logistic Models | 1 | 2004 | 13618 | 0.020 |
Why?
|
| Calcium | 1 | 2021 | 5804 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 3542 | 0.020 |
Why?
|
| Smoking | 1 | 2004 | 8980 | 0.020 |
Why?
|
| Age Factors | 1 | 2004 | 18784 | 0.020 |
Why?
|
| Patient Admission | 1 | 2014 | 1396 | 0.020 |
Why?
|
| Echocardiography | 1 | 2018 | 5044 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2020 | 4375 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 4312 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2004 | 23438 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 13217 | 0.010 |
Why?
|
| Recurrence | 1 | 2014 | 8240 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2004 | 10605 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2014 | 10499 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 2006 | 1306 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2014 | 5132 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2014 | 2980 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 7095 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2004 | 1687 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 14902 | 0.010 |
Why?
|
| ROC Curve | 1 | 2004 | 3524 | 0.010 |
Why?
|
| Adolescent | 1 | 2004 | 85155 | 0.010 |
Why?
|
| Neoplasms | 1 | 2004 | 20528 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2006 | 3580 | 0.010 |
Why?
|
| Health Surveys | 1 | 2004 | 4036 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2004 | 6259 | 0.010 |
Why?
|